The investment will be done through a convertible loan.
Cipla had earlier invested 15 million euros in Ethris in 2022.
Together, Cipla and Ethris are working towards a long-term strategic partnership to fast-track innovative mRNA-based treatments.
Ethris’ has four potential drugs under development pipeline, of which one is for treating uncontrolled asthma and three other for primary ciliary dyskinesia – a rare yet chronic respiratory disease.
During the COVID19 pandemic, mRNA vaccines gained importance due to the first regulatory approvals for SARS-CoV-2. mRNA-based medicines have a huge potential in several indications as infectious disease vaccines, therapeutic cancer vaccines, and protein replacement therapies.“The follow-on investment in Ethris will help get cutting-edge healthcare solutions like mRNA-based therapies to the Global South,” said Umang Vohra, MD & global CEO of Cipla.“The capital will enable us to continue advancing our pipeline and we look forward to providing an update on our lead program in the near term,” said Dr. Carsten Rudolph, CEO of Ethris.
